Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (25791)	9/26/1998 10:56:00 AM
From: Skeeter Bug	Read Replies (7) \| Respond to of 32384

>>In pre-clinical tests (animal and human), Targretin and LGD1268 has been shown to synergize with Resulin and Avandia and I suspect that it synergizes with the Actos also. LGND also has its own TZD program, which is being developed in part with LLY support. Looks like LGND is in the right place at the right time (Targretin and LGD1268 synergize with Tamoxifen, and Evista and probably Droloxifene, CP-366,156, and TSE424 in the SERM category for treatment and prevention of breast cancer and osteoporosis, and the rexinoids also synergize with Resulin, Avandia, and probably Actos and other TZDs in the TZD category for diabetes and other metabolic diseases like obesity. Sounds like Avandia, Actos, and Targretin will be available next year.<< henry, let's say that these synergies are factual. how long until these drugs could be used together on a mass scale? also, how big are the ontak and targretin markets that we expect approval for? tia...